Evaluating the effectiveness of a program to reduce central-line associated bloodstream infections (CLABSIs) in an intensive care unit (ICU) requires identifying the most direct and relevant measure of success. The Certification Board of Infection Control and Epidemiology (CBIC) emphasizes outcome-based assessment in the "Performance Improvement" and "Surveillance and Epidemiologic Investigation" domains, aligning with the Centers for Disease Control and Prevention (CDC) guidelines for infection prevention. The primary goal of a CLABSI reduction program is to decrease the occurrence of these infections, with secondary benefits including reduced length of stay, costs, and resource use.
Option B, "A 25% reduction in the incidence of CLABSIs over 6 months," is the best demonstration of effectiveness. The incidence of CLABSIs—defined by the CDC as the number of infections per 1,000 central line days—directly measures the program’s impact on the targeted outcome: preventing bloodstream infections associated with central lines. A 25% reduction over 6 months indicates a sustained decrease in infection rates, providing clear evidence that the intervention (e.g., improved insertion techniques, maintenance bundles, or staff education) is working. The CDC’s "Guidelines for the Prevention of Intravascular Catheter-Related Infections" (2017) and the National Healthcare Safety Network (NHSN) protocols prioritize infection rate reduction as the primary metric for assessing CLABSI prevention programs.
Option A, "A 25% decrease in the length of stay in the ICU related to CLABSIs," is a secondary benefit. Reducing CLABSI-related length of stay can improve patient outcomes and bed availability, but it is an indirect measure dependent on infection incidence. A decrease in length ofstay could also reflect other factors (e.g., improved discharge planning), making it less specific to program effectiveness. Option C, "A 30% decrease in total costs related to treatment of CLABSIs over 12 months," reflects a financial outcome, which is valuable for justifying resource allocation. However, cost reduction is a downstream effect of decreased infections and may be influenced by variables like hospital pricing or treatment protocols, diluting its direct link to program success. Option D, "A 30% reduction in the use of antibiotic-impregnated central catheters over 6 months," indicates a change in practice but not necessarily effectiveness. Antibiotic-impregnated catheters are one prevention strategy, and reducing their use could suggest improved standard practices (e.g., chlorhexidine bathing), but it could also increase infection rates if not offset by other measures, making it an ambiguous indicator.
The CBIC Practice Analysis (2022) and CDC guidelines emphasize that the primary measure of a CLABSI prevention program’s success is a reduction in infection incidence, as it directly addresses patient safety and the program’s core objective. Option B provides the most robust and specific evidence of effectiveness over a defined timeframe.
[References:, CBIC Practice Analysis, 2022., CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2017., NHSN CLABSI Surveillance Protocol, 2021., , ]
